TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized Phase II Trial Assessing the Activity of Gemcitabine - Oxaliplatin Chemotherapy Alone or in Combination With Cetuximab in Patients With Advanced Biliary Cancer.
Brief Summary: A Multicenter, Randomized Phase II Trial Assessing the Activity of Gemcitabine - Oxaliplatin Chemotherapy Alone or in Combination with Cetuximab in Patients with Advanced Biliary Cancer.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemox, Cetuximab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Gemox, Cetuximab | Intervention Type: DRUG; Name: Gemox, Cetuximab; Assigned to Arm(s): 1, 2
B: Arm Label: GEMOX; Type: ACTIVE_COMPARATOR; Interventions: Drug: gemcitabine, oxaliplatin | Arm Label: E-GEMOX; Type: EXPERIMENTAL; Interventions: Drug: cetuximab, gemcitabine, oxaliplatin | Intervention Type: DRUG; Name: gemcitabine, oxaliplatin; Assigned to Arm(s): GEMOX | Intervention Type: DRUG; Name: cetuximab, gemcitabine, oxaliplatin; Assigned to Arm(s): E-GEMOX
C: Arm Label: Arm NaI-IRI + 5-FU + Leucovorin (Arm A); Type: EXPERIMENTAL; Interventions: Drug: Arm NaI-IRI + 5-FU + Leucovorin (Arm A) | Arm Label: Arm Cisplatin + Gemcitabine (Arm B, standard of care); Type: OTHER; Interventions: Drug: Arm Cisplatin + Gemcitabine (Arm B) | Intervention Type: DRUG; Name: Arm NaI-IRI + 5-FU + Leucovorin (Arm A); Assigned to Arm(s): Arm NaI-IRI + 5-FU + Leucovorin (Arm A) | Intervention Type: DRUG; Name: Arm Cisplatin + Gemcitabine (Arm B); Assigned to Arm(s): Arm Cisplatin + Gemcitabine (Arm B, standard of care)
D: Arm Label: Gemcitabine/Oxaliplatin with Erlotinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine/Oxaliplatin with Erlotinib (Tarceva) | Arm Label: Gemcitabine/Oxaliplatin without Erlotinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine/Oxaliplatin | Intervention Type: DRUG; Name: Gemcitabine/Oxaliplatin; Assigned to Arm(s): Gemcitabine/Oxaliplatin without Erlotinib | Intervention Type: DRUG; Name: Gemcitabine/Oxaliplatin with Erlotinib (Tarceva); Assigned to Arm(s): Gemcitabine/Oxaliplatin with Erlotinib

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Methylphenidate Treatment of Children and Adolescents Diagnosed With ADHD and Its Influence on Comorbid Trichotillomania
Brief Summary: This study will evaluate the safety and effectiveness of methylphenidate in treating attention deficit hyperactivity disorder (ADHD) in children with both ADHD and trichotillomania.

Trichotillomania is an impulse control disorder. There is growing evidences of the involvement of dopaminergic neurotransmission in the pathophysiology of trichotillomania. Reported increase in the prevalence of ADHD among patients with impulse control disorders, such as pathological gambling as well as trichotillomania, may result from the overlapping pathophisiological background. It is hypothesized that in cases of ADHD comorbid with trichotillomania methtylphenidate treatment will exhibit beneficial effects in both the ADHD and the hair pulling.


Options:
A: Arm Label: N-acetylcysteine (NAC); Type: EXPERIMENTAL; Interventions: Drug: N-Acetylcysteine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: N-Acetylcysteine; Assigned to Arm(s): N-acetylcysteine (NAC) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): N/A
C: Arm Label: Dronabinol; Type: EXPERIMENTAL; Interventions: Drug: Dronabinol | Intervention Type: DRUG; Name: Dronabinol; Assigned to Arm(s): Dronabinol
D: Arm Label: N-Acetyl Cysteine; Type: ACTIVE_COMPARATOR; Interventions: Drug: N-Acetyl Cysteine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: N-Acetyl Cysteine; Assigned to Arm(s): N-Acetyl Cysteine

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Methylphenidate Treatment of Children and Adolescents Diagnosed With ADHD and Its Influence on Comorbid Trichotillomania
Brief Summary: This study will evaluate the safety and effectiveness of methylphenidate in treating attention deficit hyperactivity disorder (ADHD) in children with both ADHD and trichotillomania.

Trichotillomania is an impulse control disorder. There is growing evidences of the involvement of dopaminergic neurotransmission in the pathophysiology of trichotillomania. Reported increase in the prevalence of ADHD among patients with impulse control disorders, such as pathological gambling as well as trichotillomania, may result from the overlapping pathophisiological background. It is hypothesized that in cases of ADHD comorbid with trichotillomania methtylphenidate treatment will exhibit beneficial effects in both the ADHD and the hair pulling.


Options:
A: Arm Label: OROS-methylphenidate; Type: N/A; Interventions: N/A | Arm Label: Atomoxetine group; Type: N/A; Interventions: N/A | Arm Label: Control group; Type: N/A; Interventions: N/A
B: Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate HCl, Drug: Risperidone, Behavioral: Parent Management Training (PMT) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate HCl, Behavioral: Parent Management Training (PMT), Drug: Placebo | Intervention Type: DRUG; Name: Methylphenidate HCl; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Parent Management Training (PMT); Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' HPV Vaccine GSK580299 Administered According to an Alternative Dosing Schedule as Compared to the Standard Dosing Schedule in Young Female Subjects Aged 15-25 Years
Brief Summary: Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. The current phase 3b study is designed to assess the immunogenicity and safety of GlaxoSmithKline Biologicals' HPV vaccine GSK580299 administered according to an alternative dosing schedule as compared to the standard dosing schedule in young female subjects aged 15 - 25 years. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Options:
A: Arm Label: Gardasil®; Type: EXPERIMENTAL; Interventions: Biological: Gardasil | Arm Label: Cervarix®; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Intervention Type: BIOLOGICAL; Name: Gardasil; Assigned to Arm(s): Gardasil® | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix®
B: Arm Label: V503; Type: EXPERIMENTAL; Interventions: Biological: V503 | Arm Label: GARDASIL; Type: ACTIVE_COMPARATOR; Interventions: Biological: GARDASIL | Intervention Type: BIOLOGICAL; Name: V503; Assigned to Arm(s): V503 | Intervention Type: BIOLOGICAL; Name: GARDASIL; Assigned to Arm(s): GARDASIL
C: Arm Label: Cervarix-12 Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix TM | Arm Label: Cervarix-6 Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Cervarix TM | Intervention Type: BIOLOGICAL; Name: Cervarix TM; Assigned to Arm(s): Cervarix-12 Group | Intervention Type: BIOLOGICAL; Name: Cervarix TM; Assigned to Arm(s): Cervarix-6 Group
D: Arm Label: 16-26 year olds 3 doses HPV Vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: HPV (Human Papillomavirus) Vaccine | Arm Label: 3 dose 9-13 HPV Vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: HPV (Human Papillomavirus) Vaccine | Arm Label: 2 dose 9-13 yrs HPV Vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: HPV (Human Papillomavirus) Vaccine | Intervention Type: BIOLOGICAL; Name: HPV (Human Papillomavirus) Vaccine; Assigned to Arm(s): 16-26 year olds 3 doses HPV Vaccine, 2 dose 9-13 yrs HPV Vaccine, 3 dose 9-13 HPV Vaccine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Clinical Evaluation of Bilateral Stimulation of the Subthalamic Nucleus (STN) Using the ANS Totally Implantable Deep Brain Stimulation System as an Adjunctive Treatment for Reducing Some of the Symptoms of Advanced, Levodopa-responsive Parkinson's Disease That Are Not Adequately Controlled With Medication.
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of bilateral stimulation of the subthalamic nucleus (STN) of the brain when using the ANS Totally Implantable Deep Brain Stimulation System as an adjunctive treatment for reducing some of the symptoms of Parkinson's Disease that are not adequately controlled with medication.


Options:
A: Arm Label: Balance exercise group; Type: ACTIVE_COMPARATOR; Interventions: Other: Balance exercise | Arm Label: Mobile platform exercise group; Type: EXPERIMENTAL; Interventions: Other: Mobile platform exercise | Intervention Type: OTHER; Name: Balance exercise; Assigned to Arm(s): Balance exercise group | Intervention Type: OTHER; Name: Mobile platform exercise; Assigned to Arm(s): Mobile platform exercise group
B: Arm Label: Droxidopa; Type: EXPERIMENTAL; Interventions: Drug: Droxidopa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Droxidopa; Assigned to Arm(s): Droxidopa | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Group B; Type: PLACEBO_COMPARATOR; Interventions: Device: Libra Deep Brain Stimulation System | Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Device: Libra Deep Brain Stimulation System | Intervention Type: DEVICE; Name: Libra Deep Brain Stimulation System; Assigned to Arm(s): Group A | Intervention Type: DEVICE; Name: Libra Deep Brain Stimulation System; Assigned to Arm(s): Group B
D: Arm Label: Nicotine; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo comparator | Intervention Type: DRUG; Name: nicotine; Assigned to Arm(s): Nicotine | Intervention Type: OTHER; Name: placebo comparator; Assigned to Arm(s): placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International Randomised Trial of Early Versus Delayed Invasive Strategies in Patients With Non-ST Segment Elevation Acute Coronary Syndromes
Brief Summary: The timing of intervention study is a prospective, randomized, international, multicentre comparison of the relative efficacy, safety, and cost effectiveness of a management strategy of coronary angiography and intervention performed within 24 hours of randomization versus delayed coronary angiography and intervention in patients after 36 hours with acute coronary syndromes (ACS).


Options:
A: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Catheterization immediate PCI | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: delayed PCI | Intervention Type: PROCEDURE; Name: Catheterization immediate PCI; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: delayed PCI; Assigned to Arm(s): 1
B: Arm Label: Radial; Type: EXPERIMENTAL; Interventions: Procedure: Radial approach | Arm Label: Femoral; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Femoral approach | Intervention Type: PROCEDURE; Name: Femoral approach; Assigned to Arm(s): Femoral | Intervention Type: PROCEDURE; Name: Radial approach; Assigned to Arm(s): Radial
C: Arm Label: Prasugrel; Type: EXPERIMENTAL; Interventions: Drug: Prasugrel | Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Intervention Type: DRUG; Name: Prasugrel; Assigned to Arm(s): Prasugrel | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel
D: Arm Label: Early Coronary Intervention; Type: OTHER; Interventions: Procedure: Early Coronary Intervention | Arm Label: Delayed Coronary Intervention; Type: OTHER; Interventions: Procedure: Delayed Coronary Intervention | Intervention Type: PROCEDURE; Name: Early Coronary Intervention; Assigned to Arm(s): Early Coronary Intervention | Intervention Type: PROCEDURE; Name: Delayed Coronary Intervention; Assigned to Arm(s): Delayed Coronary Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Impact of an Antimicrobial Utilization Program on Antimicrobial Use in a Large Public Hospital: A Randomized Controlled Trial
Brief Summary: Multidisciplinary antimicrobial utilization teams (AUT) have been proposed as an effective mechanism for improving antimicrobial use, but data on their efficacy remain limited. The researchers postulated that a multi-disciplinary AUT would improve antimicrobial use in a teaching hospital when compared to the standard of care (no AUT intervention).

Design: Randomized-controlled intervention trial. Setting: A 953-bed urban teaching hospital.

Patients: Patients admitted to internal medicine ward teams who were prescribed selected antimicrobial agents (piperacillin-tazobactam, levofloxacin, or vancomycin) during the 10month study period.

Intervention: Eight internal medicine ward teams were randomized monthly to academic detailing by the AUT while 8 internal medicine ward teams were randomized indication-based prescription of broad spectrum antimicrobials.

Measurements: Proportion of appropriate empiric, definitive, and end antimicrobial usage (antimicrobial use from the initiation of therapy until definitive therapy is prescribed).


Options:
A: Arm Label: PCT guided; Type: EXPERIMENTAL; Interventions: Procedure: Earlier therapeutic changes regarding infection | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Procedure: Earlier therapeutic changes regarding infection | Intervention Type: PROCEDURE; Name: Earlier therapeutic changes regarding infection; Assigned to Arm(s): Control, PCT guided
B: Arm Label: computerized alert; Type: EXPERIMENTAL; Interventions: Drug: Trimethoprim/Sulfamethoxazole and Warfarin | Arm Label: 2 Current practice; Type: OTHER; Interventions: Drug: Trimethoprim/Sulfamethoxazole and Warfarin | Intervention Type: DRUG; Name: Trimethoprim/Sulfamethoxazole and Warfarin; Assigned to Arm(s): 2 Current practice, computerized alert
C: Arm Label: A; Type: NO_INTERVENTION; Interventions: Behavioral: Academic Detailing by the Antimicrobial Utilization Team (AUT) | Intervention Type: BEHAVIORAL; Name: Academic Detailing by the Antimicrobial Utilization Team (AUT); Assigned to Arm(s): A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Procalcitonin guided strategy | Intervention Type: PROCEDURE; Name: Procalcitonin guided strategy; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Trial of Health Coaching in Secondary Prevention of Diabetes and Heart Disease
Brief Summary: A randomised trial with individual patients as units of observation will be carried out. Health coaching is used to modify health behaviour and thus improve disease control and health status, as well as use of health care services. A personal health coach is assigned to each patient and they are in weekly contact through telephone. The intervention lasts for 12 months. No intervention is offered to the patients in the control arm.


Options:
A: Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Health coaching and and Life-long Monitoring; Type: EXPERIMENTAL; Interventions: Procedure: Health Coaching and Life-long Monitoring | Intervention Type: PROCEDURE; Name: Health Coaching and Life-long Monitoring; Assigned to Arm(s): Health coaching and and Life-long Monitoring
B: Arm Label: Early Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: ALL | Arm Label: Late implementation; Type: ACTIVE_COMPARATOR; Interventions: Other: ALL | Intervention Type: OTHER; Name: ALL; Assigned to Arm(s): Early Intervention | Intervention Type: OTHER; Name: ALL; Assigned to Arm(s): Late implementation
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Health coaching | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Health coaching; Assigned to Arm(s): 1
D: Arm Label: SMS texting intervention; Type: EXPERIMENTAL; Interventions: Behavioral: SMS texting intervention | Arm Label: Control-Usual Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Control-Usual Care | Intervention Type: BEHAVIORAL; Name: SMS texting intervention; Assigned to Arm(s): SMS texting intervention | Intervention Type: BEHAVIORAL; Name: Control-Usual Care; Assigned to Arm(s): Control-Usual Care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Trial of Health Coaching in Secondary Prevention of Diabetes and Heart Disease
Brief Summary: A randomised trial with individual patients as units of observation will be carried out. Health coaching is used to modify health behaviour and thus improve disease control and health status, as well as use of health care services. A personal health coach is assigned to each patient and they are in weekly contact through telephone. The intervention lasts for 12 months. No intervention is offered to the patients in the control arm.


Options:
A: Intervention Type: BEHAVIORAL; Name: Care Transitions Intervention; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Health coaching | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Health coaching; Assigned to Arm(s): 1
C: Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-led case management | Intervention Type: BEHAVIORAL; Name: Nurse-led case management; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): B
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Interactive Voice Response System | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-Led Group Clinic Visits | Intervention Type: BEHAVIORAL; Name: Interactive Voice Response System; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Nurse-Led Group Clinic Visits; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled Study of Mixed Amphetamine Salts (Adderall-XR) for the Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) and Cocaine Dependence
Brief Summary: The proposed protocol is a 3 group double-blind, placebo-controlled outpatient study of the safety and efficacy of Adderall-XR (ER-MAS) in the treatment of comorbid ADHD and cocaine dependence. Since this medication has independently shown promise in helping with ADHD and cocaine abuse, we are proposing that it may be successful in the treatment of comorbid ADHD and cocaine abuse. We plan to enroll 75 subjects in a 14-week trial. The primary objectives of the study are to determine the efficacy of ER-MAS in promoting cocaine abstinence and improvement in ADHD symptomology among cocaine-dependent patients with comorbid ADHD.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Adderall-XR 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Adderall-XR | Arm Label: Adderall-XR 80 mg; Type: EXPERIMENTAL; Interventions: Drug: Adderall-XR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Adderall-XR; Assigned to Arm(s): Adderall-XR 60 mg | Intervention Type: DRUG; Name: Adderall-XR; Assigned to Arm(s): Adderall-XR 80 mg
B: Arm Label: Smoking-cessation treatment + substance treatment as usual; Type: EXPERIMENTAL; Interventions: Other: Smoking-cessation treatment | Arm Label: Substance-treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Smoking-cessation treatment; Assigned to Arm(s): Smoking-cessation treatment + substance treatment as usual
C: Intervention Type: DRUG; Name: Modafinil; Assigned to Arm(s): N/A
D: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Sugar Pill or Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sugar pill or Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Sugar pill or Placebo; Assigned to Arm(s): Sugar Pill or Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled Study of Mixed Amphetamine Salts (Adderall-XR) for the Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) and Cocaine Dependence
Brief Summary: The proposed protocol is a 3 group double-blind, placebo-controlled outpatient study of the safety and efficacy of Adderall-XR (ER-MAS) in the treatment of comorbid ADHD and cocaine dependence. Since this medication has independently shown promise in helping with ADHD and cocaine abuse, we are proposing that it may be successful in the treatment of comorbid ADHD and cocaine abuse. We plan to enroll 75 subjects in a 14-week trial. The primary objectives of the study are to determine the efficacy of ER-MAS in promoting cocaine abstinence and improvement in ADHD symptomology among cocaine-dependent patients with comorbid ADHD.


Options:
A: Arm Label: SPD489; Type: ACTIVE_COMPARATOR; Interventions: Drug: SPD489 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: SPD489; Assigned to Arm(s): SPD489 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Vyvanse; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vyvanse | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vyvanse; Assigned to Arm(s): Vyvanse | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: NRP104; Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Adderall-XR 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Adderall-XR | Arm Label: Adderall-XR 80 mg; Type: EXPERIMENTAL; Interventions: Drug: Adderall-XR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Adderall-XR; Assigned to Arm(s): Adderall-XR 60 mg | Intervention Type: DRUG; Name: Adderall-XR; Assigned to Arm(s): Adderall-XR 80 mg

Answer: D